Literature DB >> 23408625

H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice.

Irina Margine1, Rong Hai, Randy A Albrecht, Gerlinde Obermoser, A Carson Harrod, Jacques Banchereau, Karolina Palucka, Adolfo García-Sastre, Peter Palese, John J Treanor, Florian Krammer.   

Abstract

Broadly neutralizing antibodies directed against the conserved stalk domain of the viral hemagglutinin have attracted increasing attention in recent years. However, only a limited number of stalk antibodies directed against group 2 influenza hemagglutinins have been isolated so far. Also, little is known about the general level of induction of these antibodies by influenza virus vaccination or infection. To characterize the anti-stalk humoral response in the mouse model as well as in humans, chimeric hemagglutinin constructs previously developed in our group were employed in serological assays. Whereas influenza virus infection induced high titers of stalk-reactive antibodies, immunization with inactivated influenza virus vaccines failed to do so in the mouse model. Analysis of serum samples collected from human individuals who were infected by influenza viruses also revealed the induction of stalk-reactive antibodies. Finally, we show that the hemagglutinin stalk-directed antibodies induced in mice and humans have broad reactivity and neutralizing activity in vitro and in vivo. The results of the study point toward the existence of highly conserved epitopes in the stalk domains of group 2 hemagglutinins, which can be targeted for the development of a universal influenza virus vaccine in humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23408625      PMCID: PMC3624338          DOI: 10.1128/JVI.03509-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans.

Authors:  J Nordin; J Mullooly; S Poblete; R Strikas; R Petrucci; F Wei; B Rush; B Safirstein; D Wheeler; K L Nichol
Journal:  J Infect Dis       Date:  2001-08-09       Impact factor: 5.226

2.  Update: influenza activity - United States, 2011-12 season and composition of the 2012-13 influenza vaccine.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2012-06-08       Impact factor: 17.586

3.  Impact of influenza vaccination on seasonal mortality in the US elderly population.

Authors:  Lone Simonsen; Thomas A Reichert; Cecile Viboud; William C Blackwelder; Robert J Taylor; Mark A Miller
Journal:  Arch Intern Med       Date:  2005-02-14

4.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.

Authors:  Y Okuno; Y Isegawa; F Sasao; S Ueda
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

5.  Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial.

Authors:  C B Bridges; W W Thompson; M I Meltzer; G R Reeve; W J Talamonti; N J Cox; H A Lilac; H Hall; A Klimov; K Fukuda
Journal:  JAMA       Date:  2000-10-04       Impact factor: 56.272

6.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

7.  Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands.

Authors:  Marion Koopmans; Berry Wilbrink; Marina Conyn; Gerard Natrop; Hans van der Nat; Harry Vennema; Adam Meijer; Jim van Steenbergen; Ron Fouchier; Albert Osterhaus; Arnold Bosman
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

Review 8.  Why do influenza virus subtypes die out? A hypothesis.

Authors:  Peter Palese; Taia T Wang
Journal:  MBio       Date:  2011-08-30       Impact factor: 7.867

9.  Influenza virus A (H10N7) in chickens and poultry abattoir workers, Australia.

Authors:  George G Arzey; Peter D Kirkland; K Edla Arzey; Melinda Frost; Patrick Maywood; Stephen Conaty; Aeron C Hurt; Yi-Mo Deng; Pina Iannello; Ian Barr; Dominic E Dwyer; Mala Ratnamohan; Kenneth McPhie; Paul Selleck
Journal:  Emerg Infect Dis       Date:  2012-05       Impact factor: 6.883

10.  Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.

Authors:  Mark Throsby; Edward van den Brink; Mandy Jongeneelen; Leo L M Poon; Philippe Alard; Lisette Cornelissen; Arjen Bakker; Freek Cox; Els van Deventer; Yi Guan; Jindrich Cinatl; Jan ter Meulen; Ignace Lasters; Rita Carsetti; Malik Peiris; John de Kruif; Jaap Goudsmit
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

View more
  86 in total

1.  Universal influenza virus vaccines: need for clinical trials.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Immunol       Date:  2014-01       Impact factor: 25.606

2.  H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge.

Authors:  Florian Krammer; Irina Margine; Rong Hai; Alexander Flood; Ariana Hirsh; Vadim Tsvetnitsky; Dexiang Chen; Peter Palese
Journal:  J Virol       Date:  2013-12-04       Impact factor: 5.103

3.  Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin.

Authors:  Peter H Goff; Florian Krammer; Rong Hai; Christopher W Seibert; Irina Margine; Adolfo García-Sastre; Peter Palese
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

Review 4.  The evolution of seasonal influenza viruses.

Authors:  Velislava N Petrova; Colin A Russell
Journal:  Nat Rev Microbiol       Date:  2017-10-30       Impact factor: 60.633

Review 5.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

6.  Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies.

Authors:  Florian Krammer; Natalie Pica; Rong Hai; Irina Margine; Peter Palese
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

7.  Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.

Authors:  Wenqian He; Caitlin E Mullarkey; J Andrew Duty; Thomas M Moran; Peter Palese; Matthew S Miller
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

8.  Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.

Authors:  Arwen F Altenburg; Carolien E van de Sandt; Stella E van Trierum; Heidi L M De Gruyter; Peter R W A van Run; Ron A M Fouchier; Kenny Roose; Xavier Saelens; Asisa Volz; Gerd Sutter; Rory D de Vries; Guus F Rimmelzwaan
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

9.  Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.

Authors:  Peter H Goff; Tomoko Hayashi; Wenqian He; Shiyin Yao; Howard B Cottam; Gene S Tan; Brian Crain; Florian Krammer; Karen Messer; Minya Pu; Dennis A Carson; Peter Palese; Maripat Corr
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

Review 10.  From Original Antigenic Sin to the Universal Influenza Virus Vaccine.

Authors:  Carole Henry; Anna-Karin E Palm; Florian Krammer; Patrick C Wilson
Journal:  Trends Immunol       Date:  2017-08-31       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.